FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1969920101> ?p ?o ?g. }

• W1969920101 endingPage "471" @default.
• W1969920101 startingPage "461" @default.
• W1969920101 abstract "Journal of Cardiovascular ElectrophysiologyVolume 10, Issue 3 p. 461-471 Antithrombotic Therapy in Nonrheumatic/Nonvalvular Atrial Fibrillation BERNARD J. GERSH M.B., Ch.B., D. Phil., FRCP, Corresponding Author BERNARD J. GERSH M.B., Ch.B., D. Phil., FRCP Mayo Clinic, Cardiovascular Diseases, Rochester, MNAddress for correspondence: Bernard J. Gersh, M.B., Ch.B., D. Phil., FRCP, Mayo Clinic, Cardiovascular Diseases, 200 First Street SW, Rochester, MN 55905. Fax:507-284-8137.Search for more papers by this author BERNARD J. GERSH M.B., Ch.B., D. Phil., FRCP, Corresponding Author BERNARD J. GERSH M.B., Ch.B., D. Phil., FRCP Mayo Clinic, Cardiovascular Diseases, Rochester, MNAddress for correspondence: Bernard J. Gersh, M.B., Ch.B., D. Phil., FRCP, Mayo Clinic, Cardiovascular Diseases, 200 First Street SW, Rochester, MN 55905. Fax:507-284-8137.Search for more papers by this author First published: 20 April 2007 https://doi.org/10.1111/j.1540-8167.1999.tb00700.xCitations: 2 Presented at “Optimal Management of Atrial Fibrillation: A Case Study Approach” symposium, November 7, 1998, Dallas, Texas. AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Reference 1 Braunwald E: Shattuck Lecture: Cardiovascular medicine at the turn of the millennium: Triumphs, concerns, and opportunities. N Engl J Med 1997; 337: 1360– 1369. 2 Murgatroyd FD, Camm AJ: Atrial arrhythmias. Lancet 1993; 341: 1317– 1322. 3 Bialy D, Leahman MH, Shuhmacher DN, et al: Hospitalization for arrhythmias in the United States: Importance of atrial fibrillation. (Abstract) J Am Coll Cardiol 1992; 19: 41. 4 Kannel WB, Abbott RD, Savage DD, et al: Epidemiologic features of chronic atrial fibrillation: The Framingham Study. N Engl J Med 1982; 306: 1018– 1022. 5 Wolf PA, Dawber TR, Thomas HE Jr, et al: Epidemiologic assessment of chronic atrial fibrillation and risk of stroke. The Framingham study. Neurology 1978; 28: 973– 977. 6 Feinberg WM, Blackshear JL, Laupacis A, et al: Prevalence, Prevalence, age distribution and gender of patients with atrial fibrillation. Arch Intern Med 1995; 155: 469– 473. 7 Wolf PA, Benjamin EJ, Belanger AJ, et al: Secular trends in the prevalence of atrial fibrillation. The Framingham Study. Am Heart J 1996; 131: 790– 795. 8 Wolf PA, Abbott RD, Kennel WB: Atrial fibrillation as an independent risk factor for stroke. The Framingham Study. Stroke 1991; 22: 983– 988. 9 Gersh BJ: The epidemiology of atrial fibrillation and atrial flutter. In JD Marco, EN Prystowsky, eds: Atrial Arrhythmias: State of the Art. Futura Publishing Co. Inc., Armonk , NY , 1995, pp. 1– 22. 10 Little RW, Otero CL, Berger AK, et al: Which patients should undergo TEE after stroke (Abstract) J Am Soc Echocardiogr 1997; 10: 394. 11 Adler Y, Koren A, Fink N, et al: Association between mitral annulus calcification and carotid atherosclerotic disease. Stroke 1998; 29: 1833– 1837. 12 Kanter MC, Tegeler CH, Pierce LA, et al: Carotid stenosis in patients with atrial fibrillation: Prevalence, risk factors, and relationship to stroke in the stroke prevention in atrial fibrillation study. Arch Intern Med 1994; 154: 1382– 1377. 13 Feinberg W, Seege JE, Carmody RF, et al: Epidemiologic features of asymptomatic cerebral infarction in patients with non-valvular atrial fibrillation. Arch Intern Med 1990; 50: 2340– 2344. 14 The Stroke Prevention in Atrial Fibrillation Investigators' Committee on Echocardiography: Transesophageal echocardiographic correlates of thromboembolism in high-risk patients with nonvalvular atrial fibrillation. Ann Intern Med 1998; 128: 639– 647. 15 Zabalgoita M, Halperin J, Pearce L, et al: Transesophageal echocardiographic correlates of clinical risk of thromboembolism in nonvalvular atrial fibrillation. J Am Coll Cardiol 1998; 31: 1622– 1626. 16 Flaker GC: Anticoagulation issues in atrial fibrillation. Cardiol Rev 1998; 6: 199– 202. 17 Stollberger C, Chnupa P, Kronik G, et al: Transesophageal echocardiography to assess embolic risk in patients with atrial fibrillation. ELAT study group. Ann Intern Med 1998; 128: 630– 638. 18 Stroke Prevention in Atrial Fibrillation Study Group Investigators: Preliminary report of the Stroke Prevention in Atrial Fibrillation Study. N Engl J Med 1990; 322: 863– 868. 19 The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators: The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. N Engl J Med 1990; 323: 1505– 1511. 20 Ezekowitz MD, Bridgers SL, James KE, et al: Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators. N Engl J Med 1992; 327: 1406– 1412. 21 Connolly SJ, Laupacis A, Gent M, et al: Canadian Atrial Fibrillation Anticoagulation (CAFA) Study. J Am Coll Cardiol 1991; 18: 349– 355. 22 Peterson P, Boysen CR, Godtfreson, et al: Placebo controlled, randomized trial of warfarin and aspirin for prevention of thromboembolitic: Complications in chronic atrial fibrillation. The Copenhagen AFASAK Study. Lancet 1989; 338: 175– 179. 23 Albers GW: Choice of antithrombotic therapy for stroke prevention in atrial fibrillation: Warfarin, aspirin, or both Arch intern Med 1998; 158: 1487– 1491. 24 Atrial Fibrillation Investigators: Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: Analysis of pooled data from five randomized controlled trials. Arch Interm Med 1994; 154: 1449– 1457. 25 Gullov A, Koefoed BG, Peterson P, et al: Aspirin alone and in combination versus adjusted-dose warfarin in atrial fibrillation. Second Copenhagen Atrial Fibrillation, Aspirin, and Anticoagulation Study. Arch Intern Med 1998; 158: 1513– 1521. 26 Stroke Prevention in Atrial Fibrillation II Investigators: Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation study. Lancet 1994; 343: 687– 691. 27 Marine JE, Goldhaber SZ: Controversies surrounding long-term anticoagulation of very elderly patients in atrial fibrillation. Chest 1998; 113: 1115– 1118. 28 Stroke Prevention in Atrial Fibrillation III Randomized Clinical Trial: Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation. Lancet 1996; 348: 633– 638. 29 European Atrial Fibrillation Trial (EAFT) Study Group: Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet 1993; 342: 1255– 1262. 30 Landefeld CS, Goldman L: Major bleeding in outpatients treated with warfarin: Incidence and prediction by factors known at the start of outpatient therapy. Am J Med 1989; 87: 144– 152. 31 Palareti G, Leali N, Coccheri S, et al: Bleeding complications of oral anticoagulant treatment: An inception-cohort, prospective collaborative study. Italian Study on Complications of Oral Anticoagulant Therapy (ISCOAT). Lancet 1996; 348: 423– 428. 32 The Stroke Prevention in Atrial Fibrillation investigators: Predictors of thromboembolism in atrial fibrillation. I. Clinical features of patients at risk. Ann Intern Med 1992 116: 1– 5. 33 The Stroke Prevention in Atrial Fibrillation Investigators: Predictors of thromboembolism in atrial fibrillation. II. Echocardiographic features of patients at risk. Ann Intern Med 1992; 116: 6– 12. 34 Manning WJ, Douglas PS: Transesophageal echocardiography and atrial fibrillation: Added value or expensive toy Ann lntern Med 1998; 128: 685– 687. 35 Sudlow M, Thomson R, Thwaites B, et al: Prevalence of atrial fibrillation and eligibility for anticoagulants in the community. Lancet 1998; 352: 1167– 1171. 36 The SPAF III Working Committee for the Stroke Prevention in Atrial Fibrillation Investigators: Patients with nonvalvular atrial fibrillation at low risk of stroke during treatment with aspirin. Stroke Prevention in Atrial Fibrillation III Study. JAMA 1998; 279; 1273– 1277. 37 Laupacis A, Albers G, Dalen J, et al: Antithrombotic therapy in atrial fibrillation. Chest 1995; 108: 3525– 3595. 38 Stroke Prevention in Atrial Fibrillation II Randomized Clinical Trial: Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation. Lancet 1996; 348: 633– 638. 39 Hylek EM, Skates SJ, Sheehan MA, et al: An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation. N Engl J Med 1996; 335: 540– 546. 40 Brodsky MA, Chun JG, Podrid PJ, et al: Regional attitudes of generalists, specialists and subspecialists about management of atrial fibrillation. Arch Intern Med 1996; 156: 2553– 2562. 41 Stafford RS, Singer DE: National patterns of warfarin use in atrial fibrillation. Arch Intern Med 1996; 156: 2537– 2541. 42 McGowan D, Flaker GC, Boechler M, et al: Factors contributing to antithrombotic under-utilization in elderly patients with atrial fibrillation. Am Heart J 1999;(In press). 43 Parkinson J, Campbell M: Paroxysmal articular fibrillation: Record of 2,000 patients. QJM 1930; 23: 67– 100. 44 Philips E, Levine SA: Auricular fibrillation without other evidence of heart disease. Am J Med 1949; 7: 4578– 4589. 45 Davidson E, Rotemberg Z, Weimbeger I: Diagnosis and characteristics of lone atrial fibrillation. Chest 1989; 95: 1048– 1050. 46 Godtfredsen J: Atrial Fibrillation: Course and Prognosis. A Follow-Up Study of 1,212 Cases. In HE Kulbertus, JB Olsson, M Schlepper, eds. Atrial Fibrillation Möndail. AB Hassle, Sweden , 1982, pp. 134– 135. 47 Brand FN, Abbott RD, Kannel WB, et al: Characteristics and prognosis of lone atrial fibrillation: 30-year follow-up in the Framingham study. JAMA 1985; 254: 3449– 3453. 48 Kopecky SL, Gersh BJ, McGoon MD, et al: The natural history of lone atrial fibrillation: A population-based study over three decades. N Engl J Med 1987; 317: 669– 674. 49 Kopecky SL, Gersh BJ, McGoon MD, et al: Lone atrial fibrillation in the elderly: A population-based long-term study. 62nd Scientific Sessions. American Heart Association. November 13–16. 1989. Circulation 1989; 80(Suppl): II– 409. 50 Scardi S, Mazzone C, Pandullo C, et al: Lone atrial fibrillation: Prognostical differences between paroxysmal and chronic forms after ten years of follow-up. Am Heart J 1999 (in press). 51 Morris JJ, Kong Y, North WC, et al: Experience with “cardioversion” of atrial fibrillation and flutter. Am J Cardiol 1964; 14: 94– 100. 52 Bjerkelund C, Orning OM: The efficacy of anticoagulation therapy in preventing embolism related to DC electrical conversation of atrial fibrillation. Am J Cardiol 1969; 23: 203– 216. 53 Weinberg DM, Mancini GBJ: Anticoagulation for cardioversion of atrial fibrillation. Am J Cardiol 1989; 63: 745– 746. 54 Arnold AZ, Mick MJ, Mazurek RP, et al: Role of prophylactic anticoagulation for direct cardioversion in patients with atrial fibrillation or atrial flutter. J Am Coll Cardiol 1992; 19: 851– 855. 55 Roy D, Marchand E, Gagne P, et al: Usefulness of anticoagulant therapy in the prevention of embolic complications of atrial fibrillation. Am Heart J 1986; 112: 1039– 1043. 56 Manning WJ, Silverman DI, Katz SE, et al: Temporal dependence of the return of atrial mechanical function on the mode of cardioversion of atrial fibrillation to sinus rhythm. Am J Cardiol 1995; 75: 624– 626. 57 Klein AL, Grimm RA, Black IW, et al: Cardioversion guided by transesophageal echocardiography: The ACUTE pilot study. A randomized, controlled trial. Ann Intern Med 1997; 126: 200– 209. 58 Manning WJ, Silvermann DI, Katz SE, et al: Impaired left atrial mechanical function after cardioversion: Relation to the duration of atrial fibrillation. J Am Coll Cardiol 1994; 23: 1535– 1540. 59 Fatkin D, Kuchar DI, Thorburn CW, et al: Transesophageal echocardiography before and during direct current cardioversion of atrial fibrillation: Evidence for “atrial stunning” as a mechanism of thromboembolic complications. J Am Coll Cardiol 1994; 23: 307– 316. 60 Crijns HJ, van Gelder IC, Lie KI: Benefits and risks of antiarrhythmic drug therapy after DC electrical cardioversion of atrial fibrillation or flutter. Eur Heart J 1994; 15 (Suppl A): 17– 21. 61 Schlicht JR, Davis RC, Naqi K, et al: Physician practices regarding anticoagulation and cardioversion of atrial fibrillation. Arch Intern Med 1996; 156: 290– 294. 62 Carlsson J, Tebbe U, Rox J, et al: Cardioversion of atrial fibrillation in the elderly. ALKK-Study Group. Arbeitsgemeinshaft Leitender Kardiologischer Krankenhauseaerzte. Am J Cardiol 1996; 78: 1380– 1384. 63 Stoddard MF, Dawkins PR, Prince CR, et al: Left atrial appendage thrombus is not uncommon in patients with acute atrial fibrillation and recent embolic event: A transesophageal echocardiographic study. J Am Coll Cardiol 1995; 25: 452– 459. 64 Weigner MJ, Caulfield TA, Danias PG, et al: Risk for clinical thromboembolism associated with conversion to sinus rhythm in patients with atrial fibrillation lasting less than 48 hours. Ann Intern Med 1997; 126: 615– 620. 65 Danias PG, Caulfieid TA, Weigner MJ, et al: Likelihood of spontaneous conversion of atrial fibrillation to sinus rhythm. J Am Coll Cardiol 1998; 31: 588– 592. 66 Manning WJ, Weintraub RM, Waksmonski CA, et al: Accuracy of transesophageal echocardiography for identifying left atrial thrombi: A prospective, intraoperative study. Ann Intern Med 1995; 123: 817– 822. 67 Manning WJ, Silvermann Di, Keighley CS, et al: Transesophageal echocardiography facilitated early cardioversion from atrial fibrillation using short-term anticoagulation: Final results of a prospective 4.5 year study. J Am Coll Cardiol 1995; 25: 1354– 1361. 68 Manning WJ, Silverman DI, Gordon SP, et al: Cardioversion from atrial fibrillation without prolonged anticoagulation with use of transesophageal echocardiography to exclude the presence of atrial thrombi. N Engl J Med 1993; 328: 750– 755. 69 Leung DY, Grimm RA, Klein AL: Transesophageal echocardiography-guided approach to cardioversion of atrial fibrillation. Prog Cardiovasc Dis 1996; 39: 21– 32. 70 Fatkin D, Scalia G, Jacobs N, et al: Accuracy of biplane transesophageal echocardiography in detecting left atrial thrombus. Am J Cardiol 1996; 77: 321– 323. 71 Stoddard MF, Dawkins PR, Prince CR, et al: Transesophageal echocardiographic guidance of cardioversion in patients with atrial fibrillation. Am Heart J 1995; 129: 1204– 1215. 72 Black IW, Fatkin D, Sagar KB, et al: Exclusion of atrial thrombus by transesophageal echocardiography does not preclude embolism after cardioversion of atrial fibrillation: A multicenter study. Circulation 1994; 89: 2509– 2513. 73 Grimm RA, Stewart WJ, Maloney JD, et al: Impact of electrical cardioversion for atrial fibrillation on left atrial appendage function and spontaneous echo contrast: Characterization by simultaneous transesophageal echocardiography. J Am Coll Cardiol 1993; 22: 1359– 1366. 74 Seto TB, Taira DA, Tsevat J, et al: Cost-effectiveness of transesophageal echocardiographic-guided cardioversion: A decision analytic model for patients admitted to the hospital with atrial fibrillation. J Am Coll Cardiol 1997; 29: 122– 130. 75 Billings JS: Medical News 1892, Vol. 60, p 230. Familiar Medical Quotations. Edited by Strauss and the Little Brown Co., Boston , Massachusetts , 1968, p. 360. 76 Coplen SE, Antman EM, Berlin JA, et al: Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion: A meta-analysis of randomized controlled trials. Circulation 1990; 82: 1106– 1116. 77 Flaker GC, Blackshear JL, McBride R, et al: Antiarrhythmic drug therapy and cardiac mortality in atrial fibrillation. J Am Coll Cardiol 1992; 20: 527– 532. 78 Wyse DG, Anderson J, Antman E, et al: Atrial fibrillation follow-up investigation of rhythm management: The AFFIRM study design. Am J Cardiol 1997; 79: 1198– 1200. 79 Singh S: Personal communication. 1998. Citing Literature Volume10, Issue3March 1999Pages 461-471 ReferencesRelatedInformation" @default.
• W1969920101 created "2016-06-24" @default.
• W1969920101 creator A5080234509 @default.
• W1969920101 date "1999-03-01" @default.
• W1969920101 modified "2023-09-23" @default.
• W1969920101 title "Antithrombotic Therapy in Nonrheumatic/Nonvalvular Atrial Fibrillation" @default.
• W1969920101 cites W1841210729 @default.
• W1969920101 cites W1965224237 @default.
• W1969920101 cites W1967514159 @default.
• W1969920101 cites W1969928268 @default.
• W1969920101 cites W1978894460 @default.
• W1969920101 cites W1980191632 @default.
• W1969920101 cites W1987034302 @default.
• W1969920101 cites W2003182429 @default.
• W1969920101 cites W2006380055 @default.
• W1969920101 cites W2007887497 @default.
• W1969920101 cites W2013832146 @default.
• W1969920101 cites W2014679230 @default.
• W1969920101 cites W2015176605 @default.
• W1969920101 cites W2017265343 @default.
• W1969920101 cites W2017870704 @default.
• W1969920101 cites W2021703221 @default.
• W1969920101 cites W2026141552 @default.
• W1969920101 cites W2039934690 @default.
• W1969920101 cites W2040452288 @default.
• W1969920101 cites W2051599542 @default.
• W1969920101 cites W2053623462 @default.
• W1969920101 cites W2063589187 @default.
• W1969920101 cites W2064428105 @default.
• W1969920101 cites W2069432912 @default.
• W1969920101 cites W2073187706 @default.
• W1969920101 cites W2075053864 @default.
• W1969920101 cites W2084719078 @default.
• W1969920101 cites W2093802454 @default.
• W1969920101 cites W2110159059 @default.
• W1969920101 cites W2112255573 @default.
• W1969920101 cites W2114775432 @default.
• W1969920101 cites W2119473125 @default.
• W1969920101 cites W2126596713 @default.
• W1969920101 cites W2127211051 @default.
• W1969920101 cites W2130622556 @default.
• W1969920101 cites W2131555931 @default.
• W1969920101 cites W2146125054 @default.
• W1969920101 cites W2150666115 @default.
• W1969920101 cites W2161283927 @default.
• W1969920101 cites W2168504637 @default.
• W1969920101 cites W2324628668 @default.
• W1969920101 cites W2329306090 @default.
• W1969920101 cites W2340349481 @default.
• W1969920101 cites W2340516904 @default.
• W1969920101 cites W2340635798 @default.
• W1969920101 cites W2346122358 @default.
• W1969920101 cites W2435343268 @default.
• W1969920101 cites W2465663631 @default.
• W1969920101 cites W2587299378 @default.
• W1969920101 cites W4205743652 @default.
• W1969920101 cites W4206535002 @default.
• W1969920101 cites W4229847571 @default.
• W1969920101 cites W4236773584 @default.
• W1969920101 cites W4237145177 @default.
• W1969920101 cites W4241650281 @default.
• W1969920101 cites W4243092031 @default.
• W1969920101 cites W4243106582 @default.
• W1969920101 cites W4244973259 @default.
• W1969920101 cites W4246465322 @default.
• W1969920101 cites W4248639063 @default.
• W1969920101 cites W4249299039 @default.
• W1969920101 cites W4253229323 @default.
• W1969920101 cites W4253306510 @default.
• W1969920101 cites W4254580080 @default.
• W1969920101 cites W4255069863 @default.
• W1969920101 cites W4255962172 @default.
• W1969920101 cites W4362054082 @default.
• W1969920101 cites W44202489 @default.
• W1969920101 cites W95402932 @default.
• W1969920101 doi "https://doi.org/10.1111/j.1540-8167.1999.tb00700.x" @default.
• W1969920101 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10210514" @default.
• W1969920101 hasPublicationYear "1999" @default.
• W1969920101 type Work @default.
• W1969920101 sameAs 1969920101 @default.
• W1969920101 citedByCount "2" @default.
• W1969920101 crossrefType "journal-article" @default.
• W1969920101 hasAuthorship W1969920101A5080234509 @default.
• W1969920101 hasConcept C126322002 @default.
• W1969920101 hasConcept C164705383 @default.
• W1969920101 hasConcept C2777015399 @default.
• W1969920101 hasConcept C2779161974 @default.
• W1969920101 hasConcept C71924100 @default.
• W1969920101 hasConceptScore W1969920101C126322002 @default.
• W1969920101 hasConceptScore W1969920101C164705383 @default.
• W1969920101 hasConceptScore W1969920101C2777015399 @default.
• W1969920101 hasConceptScore W1969920101C2779161974 @default.
• W1969920101 hasConceptScore W1969920101C71924100 @default.
• W1969920101 hasIssue "3" @default.
• W1969920101 hasLocation W19699201011 @default.
• W1969920101 hasLocation W19699201012 @default.
• W1969920101 hasOpenAccess W1969920101 @default.
• W1969920101 hasPrimaryLocation W19699201011 @default.

• next